Phase II study of L-asparaginase in the treatment of pancreatic carcinoma

H. E. Lessner; S. Valenstein; R. Kaplan; P. DeSimone; A. Yunis

Phase II study of L-asparaginase in the treatment of pancreatic carcinoma

H. E. Lessner
, S. Valenstein
, R. Kaplan
, P. DeSimone
, A. Yunis

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

L-Asparaginase was given to ten patients with advanced nonresectable pancreatic carcinoma because of the demonstration of in vitro sensitivity of the tumor to the drug. No therapeutic value was demonstrated for L-asparaginase. Toxicity was significant, mainly as evidenced by increasing mental confusion and early signs of a coagulopathy. On the basis of this limited study, L-asparaginase seems to have no value in advanced pancreatic carcinoma. The usefulness of L-asparaginase as primary therapy in patients with less advanced disease remains to be determined.

Original language	English
Pages (from-to)	1359-1361
Number of pages	3
Journal	Cancer Treatment Reports
Volume	64
Issue number	12
State	Published - 1980
Externally published	Yes

Cite this

@article{ee27f1bb1f06458abb9a3534a09fad65,

title = "Phase II study of L-asparaginase in the treatment of pancreatic carcinoma",

abstract = "L-Asparaginase was given to ten patients with advanced nonresectable pancreatic carcinoma because of the demonstration of in vitro sensitivity of the tumor to the drug. No therapeutic value was demonstrated for L-asparaginase. Toxicity was significant, mainly as evidenced by increasing mental confusion and early signs of a coagulopathy. On the basis of this limited study, L-asparaginase seems to have no value in advanced pancreatic carcinoma. The usefulness of L-asparaginase as primary therapy in patients with less advanced disease remains to be determined.",

author = "Lessner, \{H. E.\} and S. Valenstein and R. Kaplan and P. DeSimone and A. Yunis",

year = "1980",

language = "English",

volume = "64",

pages = "1359--1361",

journal = "Cancer Treatment Reports",

publisher = "U.S. National Cancer Institute",

number = "12",

}

TY - JOUR

T1 - Phase II study of L-asparaginase in the treatment of pancreatic carcinoma

AU - Lessner, H. E.

AU - Valenstein, S.

AU - Kaplan, R.

AU - DeSimone, P.

AU - Yunis, A.

PY - 1980

Y1 - 1980

N2 - L-Asparaginase was given to ten patients with advanced nonresectable pancreatic carcinoma because of the demonstration of in vitro sensitivity of the tumor to the drug. No therapeutic value was demonstrated for L-asparaginase. Toxicity was significant, mainly as evidenced by increasing mental confusion and early signs of a coagulopathy. On the basis of this limited study, L-asparaginase seems to have no value in advanced pancreatic carcinoma. The usefulness of L-asparaginase as primary therapy in patients with less advanced disease remains to be determined.

AB - L-Asparaginase was given to ten patients with advanced nonresectable pancreatic carcinoma because of the demonstration of in vitro sensitivity of the tumor to the drug. No therapeutic value was demonstrated for L-asparaginase. Toxicity was significant, mainly as evidenced by increasing mental confusion and early signs of a coagulopathy. On the basis of this limited study, L-asparaginase seems to have no value in advanced pancreatic carcinoma. The usefulness of L-asparaginase as primary therapy in patients with less advanced disease remains to be determined.

UR - https://www.scopus.com/pages/publications/0019293446

M3 - Article

C2 - 7471124

AN - SCOPUS:0019293446

VL - 64

SP - 1359

EP - 1361

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 12

ER -

Phase II study of L-asparaginase in the treatment of pancreatic carcinoma

Abstract

Fingerprint

Cite this